This likely allowed the beta IFN-IL-2 sequence to significantly boost the effector immune cells of the innate and adaptive immune response (Figures 1C, 2) as demonstrated by the highly significant increase in total lymphocytes, CD8+, CD4+ T cells and NK cells reported during the clinical benefit of the studied breast cancer patients (115, 117). The gene discussed is IL2; the disease is breast cancer.